Prosecution Insights
Last updated: November 04, 2026
Application No. 18/054,508

SYNTHESIS METHOD OF TARGETED DRUG nCoVshRNA 2ACE2

Final Rejection §103§112
Filed
Nov 10, 2022
Priority
Nov 11, 2021 — CN 202111329892.6 +4 more
Examiner
POLIAKOVA-GEORGAN, EKATERINA
Art Unit
1637
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hangzhou Chichuang Biotechnology Co. Ltd.
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
440 granted / 690 resolved
+3.8% vs TC avg
Strong +18% interview lift
Without
With
+18.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
58 currently pending
Career history
763
Total Applications
across all art units

Statute-Specific Performance

§101
6.9%
-33.1% vs TC avg
§103
27.7%
-12.3% vs TC avg
§102
19.2%
-20.8% vs TC avg
§112
27.1%
-12.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 690 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 30-32 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 30-31 refer to GenBank reference number “NC_045512.2”. Such reference numbers generally get updated and changed, therefore reference to such number makes the claim indefinite. It is suggested to replace such reference number with SEQ ID NO. Further, the purpose of the screening step of the method in claim 30 is unclear, because in the same step siRNAs resulting from such screening are already defined and listed. It is suggested to exclude screening step from the method. Claim 32 refers to siRNA in line 8, while the claim is related to verifying activity of shRNA, so that it is not clear which siRNA the claim refers to. Further, it is not clear at all how the actual validation of shRNA activity happens. Appropriate correction is required. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 31 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 31 depends on claim 30 and recites the same limitation as in claim 30: “synthesizing siRNAs comprises performing screening on a plurality of sequences to obtain the sequences of SEQ ID NO: 16 to 18, SEQ ID NO: 20 to 22, SEQ ID NO: 30 to 32, SEQ ID NO: 49 to 51, SEQ ID NO: 52 to 54, SEQ ID NO: 56 to 58”. Other steps in the claim essentially identify specific SEQ ID NOs from the same list, which are already identified. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 30-34 is/are rejected under 35 U.S.C. 103 as being unpatentable over Li (CN 113355288, September 2021, cited from machine translation, of record) and in further view of Loibner et al (WO 2008/046125, April 2008), Okamoto et al (US 2012/0238038, September 2012), Ebben et al (WO 2023/023597, claiming priority to 63/234478, filed August 2021, of record), Leavitt et al (US 2009/0123501, May 2009, of record), Ghosh et al (Bioconjugate Chemistry, 1990, 1(1): 71-76) and Weng et al (CN 111321142, June 2020). Li et al teach T-cell modified to express ACE2 capable of binding to SARS-CoV-2 for treatment of COVID-19 (see Abstract). Such T-cell can further comprise coding gene for shRNA targeting SARS-CoV-2, which can be expressed (see page 6). The shRNA aims to destroy SARS- CoV-2 genome in a cell targeted by ACE2 (see page 10). Li do not teach ACE2 of instant SEQ ID NO: 59 synthesized using peptide synthesizer by solid phase synthesis from C-terminus to N-terminus, or conjugation of ACE2 to both ends of shRNA based on siRNA of SEQ ID NO: 21 using maleimide-thiol coupling, or screening for siRNAs shared by all novel coronavirus strains, or construction of shRNA expression vector using pSilencer4.1.CMV.neo, pEGFP vector expressing ORF1ab or S gene using PCR and validating RNAi effect in 293T cells. Loibner teach the sequence of ACE2 on Figure 4, which is identical to instant SEQ ID NO: 59 (see Figure 4). Okamoto teach synthesizing peptides using peptide synthesizer by solid phase synthesis from C-terminus to N-terminus by sequential connection of amino acids with protected N-amino groups and consecutive removal of such group before connection to the next amino acid (see paragraph [0080]). Ebben teach virus-like particles comprising siRNAs and shRNAs targeting SARS-CoV- 2, such siRNA or shRNA delivered by liposome (see paragraphs [0014-0017]). One of such siRNAs is of SEQ ID NO: 12 (see Table 1), 21 nucleotides long, and fully identical to instant SEQ ID NO: 21. shRNA is formed by connecting two complementary strands of siRNA at one end by a loop of 2-10 nucleotides (see paragraph [0073]). Ebben teach screening of siRNAs optimized to inhibit viral replication (see first two lines on page 40). Leavitt et al teach shRNA-protein conjugates (see paragraph [0151]). Ghosh teach conjugation of enzyme to oligonucleotide by modifications of each one with maleimide and thiol residues with further formation of conjugate (see Abstract). Weng teach identification of shRNAs targeting different genes of SARS-CoV-2 virus (see page 6 of machine translation), construction of shRNA expression vector based on pSilencer4.1.CMV.neo vector (see page 8 of machine translation), construction of pEGFP vector expressing ORF1ab or S gene using PCR (see page 9 of machine translation) and validation of RNAi effect in 293T cells (see page 9 of machine translation). It would have been obvious to one of the ordinary skill in the art before the effective filing date of the claimed invention to conjugate shRNA taught by Ebben to ACE2 protein taught by Li and Loibner and synthesized by method taught by Okamoto as taught by Leavitt using maleimide-thiol conjugation taught by Ghosh and validate RNAi activity of shRNA based on teachings of Weng, arriving at instant invention. One of the ordinary skill in the art would be motivated to do so because Li teach a cell expressing two compounds targeting SARS-CoV- 2: ACE2 protein capable of binding to the virus and siRNA capable of destroying viral genome, therefore treating the viral infection, motivating one of the art to combine both elements taught by Li in one conjugate by attaching ACE2 proteins to both ends of shRNA so that ACE2 protein targets the shRNA to viral particle, because such shRNA-protein conjugates are known in the art as taught by Leavitt. Okamoto teach an effective method of protein synthesis, which can be applied for synthesizing ACE2 protein taught by Loibner. Ghosh teach an effective way of conjugation of oligonucleotide, which can be shRNA, to protein, which can be ACE2. Further, Weng provide teachings to validate activity of shRNAs, allowing to identify most effective shRNAs targeting different genes of SARS-CoV-2 virus. Terminal Disclaimer The terminal disclaimer filed on 08/25/2026 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 18/054212 has been reviewed and is accepted. The terminal disclaimer has been recorded. Response to Arguments All previous claims were cancelled by Applicant, therefore any arguments are moot. Applicant is highly encouraged to contact Examiner by phone for assistance in further amendments and identification of patentable subject matter. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EKATERINA POLIAKOVA whose telephone number is (571)270-5257. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Dunston can be reached at (571)272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /EKATERINA POLIAKOVA-GEORGANTAS/Primary Examiner, Art Unit 1637
Read full office action

Prosecution Timeline

Nov 10, 2022
Application Filed
Jul 15, 2025
Non-Final Rejection mailed — §103, §112
Dec 15, 2025
Response Filed
Dec 15, 2025
Response after Non-Final Action
Mar 13, 2026
Response Filed
Mar 13, 2026
Response after Non-Final Action
Aug 03, 2026
Response Filed
Oct 22, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781274
Novel Replicase Cycling Reaction (RCR) and the Related RdRP-Binding Site Designs Thereof
3y 1m to grant Granted Nov 03, 2026
Patent 12781232
BACTERIAL CONTINUOUS EVOLUTION SYSTEM, ORTHOGONAL ERROR-PRONE DNA POLYMERASE, AND CONTINUOUS EVOLUTION METHOD
2y 11m to grant Granted Nov 03, 2026
Patent 12774310
POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
3y 5m to grant Granted Oct 27, 2026
Patent 12767946
OLIGONUCLEOTIDES FOR TISSUE SPECIFIC APOE MODULATION
6y 7m to grant Granted Oct 20, 2026
Patent 12735705
COMPOUND, METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING EXPRESSION OF ATAXIN 3
3y 10m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
82%
With Interview (+18.3%)
2y 7m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 690 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month